Lovotibeglogene autotemcel, sold under the brand name Lyfgenia, is a lentiviral gene therapy used for the treatment of sickle cell disease. From Wikipedia
Recent FDA approvals mark a significant advancement in the treatment of sickle cell disease, potentially transforming patient lives and addressing long-standing inequities in healthcare.
